Ardelyx

Ardelyx, Inc. is a biopharmaceutical company. engages in the research, development and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ardelyx reports strong Q4 earnings, poised for product expansion

Ardelyx's Q4 performance reflects revenue growth, improved financial efficiency, and progress towards expanding its product portfolio.
While facing challenges such as regulatory processes and market competition, Ardelyx's strengths lie in successful product launches and a proactive commercial strategy.
Opportunities for Ardelyx include leveraging positive feedback for XPHOZAH, raising additional funds for growth, and diversifying revenue through new product launches.

Ardelyx reports sales growth, readies XPHOZAH launch amid challenges

Ardelyx showed strong sales growth for IBSRELA and is poised for the XPHOZAH launch
Financially, the company raised significant funds and maintains a healthy cash position
Challenges include managing expenses and improving profitability amidst losses
Opportunities lie in upcoming product launches and optimizing financial operations

Ardelyx reports strong Q2 performance amidst legislative challenges and growth opportunities

Ardelyx's Q2 performance reflects growth in IBSRELA sales and overall revenue, despite incurring a net loss.
The company faces challenges from pending legislation and financial burdens related to XPHOZAH launch preparation.
Opportunities lie in the potential of XPHOZAH launch, market reception of IBSRELA, and addressing legislative impacts.

Ardelyx reports strong Q3 earnings, poised for successful XPHOZAH launch

Ardelyx's Q3 performance reflects financial strength and positive market reception for IBSRELA.
Challenges in pricing strategy and market competition require strategic planning for XPHOZAH's launch.
Opportunities lie in leveraging financial stability, physician interest, and promotional activities for XPHOZAH success.
The company's commitment to patient access and learnings from IBSRELA will drive future growth and market penetration.

Ardelyx reports strong revenue growth driven by IBSRELA success

Ardelyx is strategically investing in growth, focusing on sustaining momentum for its products. The company is well-resourced and optimistic about the future performance of IBSRELA and XPHOZAH. Despite challenges in operating expenses, Ardelyx remains committed to its commercialization efforts.

Ardelyx reports robust Q1 performance driven by XPHOZAH success

Ardelyx's Q1 2024 earnings call showcased strong revenue growth, particularly driven by XPHOZAH and IBSRELA. The company's cash position remains healthy, and there is a clear focus on expanding market reach and driving adoption of key therapies.

Ardelyx reports robust Q2 earnings, focuses on patient access advocacy

Ardelyx's Q2 2024 performance reflects strong revenue growth driven by IBSRELA and XPHOZAH, with a focus on shareholder value and patient access advocacy. While facing challenges in legal battles and expense management, the company is poised to capitalize on opportunities through sales force expansion and market differentiation strategies.

Ardelyx (ARDX) reports robust Q3 earnings, navigates Medicare coverage challenges

Ardelyx's Q3 earnings call highlighted strong financial performance, success of key medications, and strategies to address Medicare coverage challenges. The company's focus on patient access, commitment to therapy availability, and positive market impact showcase its growth potential and resilience in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Majority of survey respondents call for new treatments to help manage phosphorus levels WALTHAM, Mass. and NEW YORK , Nov. 4, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX) in partnership with the National Kidney Foundation (NKF), today announced results from a survey of patients with chronic kidney disease (CKD) on dialysis conducted to better understand patients' experience managing serum phosphorus levels.

National Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus Levels

Ardelyx (ARDX) delivered earnings and revenue surprises of 17.65% and 86.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Ardelyx (ARDX) Reports Q3 Loss, Tops Revenue Estimates

Conference call scheduled for 4:30 p.m. Eastern Time today WALTHAM, Mass.

Ardelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights

XPHOZAH monotherapy lowers serum phosphorus with early responders maintaining response with continued treatment XPHOZAH monotherapy meaningfully reduced serum phosphorus in patients with severe hyperphosphatemia XPHOZAH in combination with phosphate binders reduced patients' interdialytic weight gain compared to binders alone WALTHAM, Mass. , Nov. 3, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that new analyses of data from its three Phase 3 trials supporting the clinical utility of XPHOZAH (tenapanor) will be presented at the American Society of Nephrology (ASN) Kidney Week 2022, taking place in Orlando, Florida from November 3-6, 2022.

Ardelyx Presents New Data Analyses at Kidney Week 2022, Further Supporting the Clinical Relevance of XPHOZAH® (tenapanor), an Investigational, Phosphate Absorption Inhibitor to Control Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dial

Ardelyx to receive an aggregate of $35 million in milestone payments and payments associated with the recent amendment of the license agreement WALTHAM, Mass. , Oct. 31, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that its collaboration partner in Japan, Kyowa Kirin Co., Ltd.

Ardelyx Collaboration Partner, Kyowa Kirin, Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan

- Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass.

Ardelyx to Report Third Quarter 2022 Financial Results on November 3, 2022

WALTHAM, Mass. , Oct. 24, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that post-hoc analyses from its Phase 3 T3MPO trials will be presented in two posters at the 2022 American College of Gastroenterology Annual Scientific Meeting (ACG 2022) taking place in Charlotte, North Carolina from October 21-26, 2022 and virtually.

Ardelyx to Present Poster Presentations on IBSRELA® (tenapanor) for Adult Patients with IBS-C at the American College of Gastroenterology 2022 Annual Scientific Meeting

Tenapanor's approved indication for IBS is enjoying early signs of market success. Ardelyx shares are running up toward the ADCOM decision for tenapanor's label expansion for hyperphosphatemia which is tentatively set for November 16.

Ardelyx: Big Transitional Period

WALTHAM, Mass. , Oct. 20, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced three posters will be presented at the American Society of Nephrology (ASN) Kidney Week 2022 to be held November 3-6, 2022, in Orlando, Florida.

Ardelyx Announces Poster Presentations on XPHOZAH® (tenapanor) at ASN's Kidney Week 2022

The FDA will convene an Advisory Committee on November 16 to discuss the new drug application for XPHOZAH. Background material will be available to the public two business days before the meeting.

What To Expect For Ardelyx In The Coming Month

Amyris

Transocean

Penny stocks with unusual options activity to watch today. The post Penny Stocks To Buy Now: 3 To Watch With Unusual Options Activity Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy Now: 3 To Watch With Unusual Options Activity Today

Aprea Therapeutics

Gritstone Oncology Inc

Seelos Therapeutics

Red Hot Biotech Penny Stocks To Watch Right Now The post Why The Stock Market Is Down Today & 4 Penny Stocks To Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Why The Stock Market Is Down Today & 4 Penny Stocks To Watch

Avaya Holdings

23andMe

Nutex Health Inc

Penny stocks to buy according to top money managers. The post 4 Hot Penny Stocks To Buy Now According To Top Hedge Funds appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Hot Penny Stocks To Buy Now According To Top Hedge Funds

WALTHAM, Mass. , Sept. 6, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences: Citi's 17th Annual BioPharma Conference Location: Boston, MA 1x1 Meetings: Thursday, September 8, 2022 H.C.

Ardelyx to Participate in Upcoming Investor Conferences

Bright Minds Biosciences

ironSource Ltd

MannKind

Are these penny stocks to buy now or avoid in September? The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 4 To Watch This Month

Ardelyx, Inc. (NASDAQ:ARDX ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Justin Renz - CFO & Treasurer Michael Raab - President, CEO & Director Susan Rodriguez - Chief Commercial Officer Robert Blanks - Chief Regulatory Affairs & Quality Assurance Officer Conference Call Participants Christopher Howerton - Jefferies Matthew Kaplan - Ladenburg Thalmann & Co. John Bohnsack - Cowen and Company Operator Good afternoon, and welcome to the Ardelyx's Second Quarter 2022 Conference Call. [Operator Instructions].

Ardelyx, Inc. (ARDX) CEO Michael Raab on Q2 2022 Results - Earnings Call Transcript

Ardelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights

WALTHAM, Mass. , Aug. 2, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a virtual fireside chat at the 2022 Wedbush PacGrow Healthcare Conference.

Ardelyx to Present at the 2022 Wedbush PacGrow Healthcare Conference

— Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass.

Ardelyx to Report Second Quarter 2022 Financial Results on August 4, 2022

Wilmington, Delaware--(Newsfile Corp. - July 22, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Ardelyx, Inc. (NASDAQ: ARDX) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-ardelyx-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Ardelyx, Inc.

NeuroSense Therapeutics Ltd

Revelation Biosciences

Penny stocks for your watch list with the stock market down today. The post 3 Penny Stocks To Watch While The Stock Market Is Down appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks To Watch While The Stock Market Is Down

HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA® in the United States in exchange for future hyperphosphatemia royalty payments from Ardelyx Japanese collaboration partner WALTHAM, Mass. , June 30, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that the company may receive up to $20 million from HealthCare Royalty Partners (HealthCare Royalty) from the sale of its future royalties and sales milestones from Kyowa Kirin Co., Ltd (Kyowa Kirin), its collaboration partner in Japan for the commercialization of tenapanor for hyperphosphatemia.

Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners

WALTHAM, Mass. , June 21, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has informed the company that a meeting of the Cardiovascular and Renal Drugs Advisory Committee (Advisory Committee) is tentatively scheduled for November 16, 2022.

Ardelyx Announces FDA Advisory Committee Meeting to Review XPHOZAH® NDA Tentatively Scheduled for November 16, 2022

WALTHAM, Mass. , June 3, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 10, 2022, at 8:30 a.m.

Ardelyx to Present at the Jefferies 2022 Healthcare Conference

Three poster presentations continue to highlight the safety and efficacy of IBSRELA based on data from two Phase 3 trials in adults with irritable bowel syndrome with constipation (IBS-C) WALTHAM, Mass. , May 24, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that new analyses from IBSRELA Phase 3 trials, T3MPO-1 and T3MPO-2, were presented in three poster presentations at the 2022 Digestive Disease Week Conference (DDW 2022) that is now underway in San Diego, California and virtually.

News for Ardelyx Stock (ARDX)